stockrowViridian Therapeutics, Inc.
VRDN Healthcare Biotechnology
Viridian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.8 million, up 23,359.9% from fiscal 2024.
- Revenue
- −63.5%
- EPS
- −5.00%
- Free cash flow
- −9.92%
- Total debt
- +1,064.9%
Quarter to September 2026, against a year earlier
Follow VRDN
Alert me
Viridian Therapeutics, Inc. (VRDN) Revenue growth
Viridian Therapeutics, Inc.'s revenue growth over the twelve months to 30 September 2026 was −62.8%, down 23422.8 percentage points from fiscal 2025 (23,359.9%). Over the past ten years it has ranged from −82.3% (fiscal 2023) to 23,359.9% (fiscal 2025) — the current reading is the highest in ten years. That is below the Biotechnology industry median of 6.26% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 23,359.9% | 23,363.75 |
| FY2024 | −3.82% | 78.46 |
| FY2023 | −82.3% | (42.08) |
| FY2022 | −40.2% | (222.39) |
| FY2021 | 182.2% | 258.65 |
| FY2020 | −76.5% | (29.66) |
| FY2019 | −46.8% | (156.29) |
| FY2018 | 109.5% | 94.36 |
| FY2017 | 15.1% | (21.87) |
| FY2016 | 37.0% | 78.25 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | −63.5% | (342.18) |
| Jun 2026 | 278.7% | 182.84 |
| Mar 2026 | 95.8% | 12.50 |
| Dec 2025 | 83.3% | (81,874.81) |
| 42 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| TARS Tarsus Pharmaceuticals, Inc. compare | 86.3% |
| VRDN Viridian Therapeutics, Inc. | −62.8% |
| IDYA IDEAYA Biosciences, Inc. compare | −83.6% |
| DNLI Denali Therapeutics Inc. compare | −93.4% |
| VKTX Viking Therapeutics, Inc. compare | — |
| TLX Telix Pharmaceuticals Limited compare | — |
| CELC Celcuity, Inc. compare | — |
| DYN Dyne Therapeutics, Inc. compare | — |
| ELVN Enliven Therapeutics, Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on VRDN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- The full statement